Cumberland Pharmaceuticals Announces Data From Its Phase 2 ASSIST-SSc Study Of Oral Ifetroban For Patients With Systemic Sclerosis; Gastrointestinal Adverse Events Were More Frequent In Ifetroban Group Than Placebo; Majority Of Patients Demonstrated Limited Disease Progression, Which Reduced Ability To Track Treatment Difference
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, announces top-line results from its Phase 2a
Cumberland tested a new medicine for a serious disease. More people got stomach problems with the medicine than expected, which makes the results harder to understand clearly.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.